Alerts will be sent to your verified email
Verify Email
NORRIS
|
Norris Medicines
|
Saroja Pharma Ind
|
Emmessar Biotech&Nut
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
25.68 % | 27.98 % | 10.99 % |
|
5yr average Equity Multiplier
|
-1.27 | 4.23 | 1.23 |
|
5yr Average Asset Turnover Ratio
|
0.6 | 2.66 | 0.25 |
|
5yr Avg Net Profit Margin
|
-27.67 % | 2.05 % | 77.44 % |
|
Price to Book
|
0.0 | 0.89 | 1.75 |
|
P/E
|
0.0 | 14.01 | 41.56 |
|
5yr Avg Cash Conversion Cycle
|
113.0 Days | 72.5 Days | 63.13 Days |
|
Inventory Days
|
182.62 Days | 9.36 Days | 54.75 Days |
|
Days Receivable
|
77.44 Days | 145.45 Days | 11.98 Days |
|
Days Payable
|
195.35 Days | 53.02 Days | 169.78 Days |
|
5yr Average Interest Coverage Ratio
|
-1.07 | 2.62 | 820.35 |
|
5yr Avg ROCE
|
-18.91 % | 33.47 % | 17.27 % |
|
5yr Avg Operating Profit Margin
|
-2.35 % | 4.85 % | -130.11 % |
|
5 yr average Debt to Equity
|
-1.84 | 1.55 | 0.0 |
|
5yr CAGR Net Profit
|
-24.21 % | 7.13 % | -26.08 % |
|
5yr Average Return on Assets
|
-17.47 % | 5.43 % | 8.75 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
34.0 % | 73.02 % | 59.53 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
-0.04 % | 0.0 | 1.0 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Norris Medicines
|
Saroja Pharma Ind
|
Emmessar Biotech&Nut
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|